OBJECTIVE: A fundamental metric in the diagnosis of arthropathies is the pattern of joint involvement, including differences in proximal versus distal joints and patterns of symmetric or asymmetric disease. The basis for joint selectivity among arthritides and/or within a defined disease such as rheumatoid arthritis remains enigmatic. Coagulation and fibrinolytic activity are observed in both experimental animals with inflammatory joint disease and patients with inflammatory arthritis. However, the contribution of specific hemostatic factors to joint disease is not fully defined. We sought to determine the contribution of the fibrinolytic protease, plasminogen, to tumor necrosis factor α (TNFα)-driven arthritis in distinct joints in mice. METHODS: The impact of plasminogen and/or fibrinogen genetic deficiencies on arthritis progression was evaluated in Tg197 mice genetically predisposed to spontaneous, nonabating, and erosive polyarthritis due to exuberant human TNFα expression. RESULTS: Elimination of plasminogen in Tg197 mice significantly exacerbated the incidence and severity of arthritis within the paw joints, but simultaneously and dramatically diminished the entire spectrum of pathologies within the knee joints of the same animals. These opposing outcomes were both mechanistically linked to fibrin(ogen), in that superimposing fibrinogen deficiency reversed both the proarthritic phenotype in the paws and arthritis resistance in the knees of plasminogen-deficient mice. Intriguingly, the change in disease severity in the knees, but not the paws, was associated with a plasminogen-dependent reduction in matrix metalloproteinase 9 activity. CONCLUSION: Plasminogen is a key molecular determinant of inflammatory joint disease capable of simultaneously driving or ameliorating arthritis pathogenesis in distinct anatomic locations in the same subject.
OBJECTIVE: A fundamental metric in the diagnosis of arthropathies is the pattern of joint involvement, including differences in proximal versus distal joints and patterns of symmetric or asymmetric disease. The basis for joint selectivity among arthritides and/or within a defined disease such as rheumatoid arthritis remains enigmatic. Coagulation and fibrinolytic activity are observed in both experimental animals with inflammatory joint disease and patients with inflammatory arthritis. However, the contribution of specific hemostatic factors to joint disease is not fully defined. We sought to determine the contribution of the fibrinolytic protease, plasminogen, to tumor necrosis factor α (TNFα)-driven arthritis in distinct joints in mice. METHODS: The impact of plasminogen and/or fibrinogen genetic deficiencies on arthritis progression was evaluated in Tg197mice genetically predisposed to spontaneous, nonabating, and erosive polyarthritis due to exuberant humanTNFα expression. RESULTS: Elimination of plasminogen in Tg197mice significantly exacerbated the incidence and severity of arthritis within the paw joints, but simultaneously and dramatically diminished the entire spectrum of pathologies within the knee joints of the same animals. These opposing outcomes were both mechanistically linked to fibrin(ogen), in that superimposing fibrinogen deficiency reversed both the proarthritic phenotype in the paws and arthritis resistance in the knees of plasminogen-deficient mice. Intriguingly, the change in disease severity in the knees, but not the paws, was associated with a plasminogen-dependent reduction in matrix metalloproteinase 9 activity. CONCLUSION:Plasminogen is a key molecular determinant of inflammatory joint disease capable of simultaneously driving or ameliorating arthritis pathogenesis in distinct anatomic locations in the same subject.
Authors: Matthew J Flick; Anil K Chauhan; Malinda Frederick; Kathryn E Talmage; Keith W Kombrinck; Whitney Miller; Eric S Mullins; Joseph S Palumbo; Xunzhen Zheng; Naomi L Esmon; Charles T Esmon; Sherry Thornton; Ann Becker; Leslie A Pelc; Enrico Di Cera; Denisa D Wagner; Jay L Degen Journal: Blood Date: 2011-03-24 Impact factor: 22.113
Authors: Andrew D Cook; Christine M De Nardo; Emma L Braine; Amanda L Turner; Ross Vlahos; Kerrie J Way; S Kaye Beckman; Jason C Lenzo; John A Hamilton Journal: Arthritis Res Ther Date: 2010-03-02 Impact factor: 5.156
Authors: Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone Journal: Arthritis Rheum Date: 2008-01
Authors: Matthew J Flick; Christine M LaJeunesse; Kathryn E Talmage; David P Witte; Joseph S Palumbo; Malinda D Pinkerton; Sherry Thornton; Jay L Degen Journal: J Clin Invest Date: 2007-11 Impact factor: 14.808
Authors: Christine M De Nardo; Jason C Lenzo; Jarrad Pobjoy; John A Hamilton; Andrew D Cook Journal: Arthritis Res Ther Date: 2010-10-25 Impact factor: 5.156
Authors: Lindsey A Miles; Shahrzad Lighvani; Nagyung Baik; Nicholas M Andronicos; Emily I Chen; Caitlin M Parmer; Sophia Khaldoyanidi; Jenna E Diggs; William B Kiosses; Mark P Kamps; John R Yates; Robert J Parmer Journal: J Biomed Biotechnol Date: 2012-10-14
Authors: Lakmali Munasinghage Silva; Andrew Gary Lum; Collin Tran; Molly W Shaw; Zhen Gao; Matthew J Flick; Niki M Moutsopoulos; Thomas H Bugge; Eric S Mullins Journal: Blood Date: 2019-05-17 Impact factor: 22.113
Authors: Maureen A Shaw; Zhen Gao; Kathryn E McElhinney; Sherry Thornton; Matthew J Flick; Adam Lane; Jay L Degen; Jae Kyu Ryu; Katerina Akassoglou; Eric S Mullins Journal: J Neurosci Date: 2017-03-08 Impact factor: 6.167
Authors: Sherry Thornton; Harini Raghu; Carolina Cruz; Malinda D Frederick; Joseph S Palumbo; Eric S Mullins; Kasper Almholt; Pernille A Usher; Matthew J Flick Journal: Blood Adv Date: 2017-03-21